PARP抑制剂单药及联合方案治疗晚期或复发性子宫内膜癌有效性与安全性的网状Meta分析
x

请在关注微信后,向客服人员索取文件
| 篇名: | PARP抑制剂单药及联合方案治疗晚期或复发性子宫内膜癌有效性与安全性的网状Meta分析 |
| TITLE: | Efficacy and safety of PARP inhibitor monotherapy and combination regimens for advanced or recurrent endometrial cancer:a network meta-analysis |
| 摘要: | 目的 比较聚腺苷二磷酸核糖聚合酶抑制剂(PARPi)单药及其不同联合方案用于晚期或复发性子宫内膜癌(EC)的疗效与安全性。方法检索PubMed、Embase、TheCochraneLibrary、WebofScience、中国知网、万方数据库,收集PARPi单药、PARPi联合免疫检查点抑制剂(ICI)和PARPi联合抗血管生成药物(AA)以及可为上述方案提供直接或间接比较证据(ICI单药、AA单药、ICI联合AA及传统化疗)的随机对照试验(RCT),检索时限为建库起至2026年3月10日。筛选文献、提取数据、评价文献质量后,采用Stata18.0和R语言4.5.2软件进行网状Meta分析。结果共纳入12项研究,共计5059例患者。使用PARPi单药、PARPi联合ICI及PARPi联合AA患者的无进展生存期(PFS)比较,差异均无统计学意义(P>0.05);与传统化疗比较,使用ICI单药、PARPi联合ICI、PARPi联合AA、ICI联合AA患者的PFS均显著延长(P<0.05);累积排序曲线下面积(SUCRA)排名由高到低依次为PARPi联合AA>AA单药>PARPi联合ICI>ICI联合AA>PARPi单药>ICI单药>传统化疗。各干预措施间的客观缓解率比较,差异均无统计学意义(P>0.05);SUCRA排名由高到低依次为ICI联合AA>PARPi联合AA>ICI单药>AA单药>传统化疗>PARPi单药。与PARPi联合ICI及PARPi单药比较,使用PARPi联合AA患者的≥3级AEs发生率均显著升高(P<0.05);SUCRA排名由高到低依次为传统化疗>ICI单药>PARPi联合ICI>ICI联合AA>PARPi单药>AA单药>PARPi联合AA。结论PARPi联合ICI、PARPi联合AA在晚期或复发性EC患者中均显示出一定的PFS获益,但PARPi联合ICI的安全性更优。 |
| ABSTRACT: | OBJECTIVE To compare the efficacy and safety of poly(ADP-ribose) polymerase inhibitor (PARPi) monotherapy and its different combination regimens in the treatment of advanced or recurrent endometrial cancer.METHODS PubMed, Embase, The Cochrane Library, Web of Science, CNKI, and Wanfang Data were searched to identify randomized controlled trials (RCT) of PARPi monotherapy, PARPi+immune checkpoint inhibitor (ICI), and PARPi+anti-angiogenic agent (AA), as well as RCT providing direct or indirect comparative evidence for the above regimens, including ICI monotherapy, AA monotherapy, ICI+AA, and conventional chemotherapy. The search period was from database inception to March 10, 2026. After literature screening, data extraction, and quality assessment, a network meta-analysis was performed using Stata 18.0 and R 4.5.2.RESULTS A total of 12 studies were included,involving 5 059 patients. There was no statistically significant difference in progression free survival (PFS) among patients treated with PARPi monotherapy, PARPi+ICI, and PARPi+AA ( P >0.05).Compared with conventional chemotherapy, ICI monotherapy, PARPi+ICI, PARPi+AA, and ICI+AA significantly prolonged PFS ( P <0.05). According to surface under the cumulative ranking curve (SUCRA), the ranking was PARPi+AA>AA monotherapy>PARPi+ICI>ICI+AA>PARPi monotherapy>ICI monotherapy>conventional chemotherapy. There were no statistically significant difference in objective response rate among the interventions ( P >0.05);the SUCRA ranking was ICI+AA>PARPi+AA>ICI monotherapy>AA monotherapy>conventional chemotherapy>PARPi monotherapy. Compared with PARPi+ICI and PARPi monotherapy, the incidence of grade ≥3 adverse events was significantly higher in patients receiving PARPi+AA ( P <0.05);the SUCRA ranking was conventional chemotherapy>ICI monotherapy>PARPi+ICI>ICI+AA>PARPi monotherapy>AA monotherapy>PARPi+AA.CONCLUSIONS PARPi+ICI and PARPi+AA showed certain PFS benefits in patients with advanced or recurrent endometrial cancer, while PARPi+ICI had a more favorable safety profile. |
| 期刊: | 2026年第37卷第21期 |
| 作者: | 梁孜;刘天琦;李瑞雪;赵紫楠;徐文峰;金鹏飞 |
| AUTHORS: | LIANG Zi,LIU Tianqi,LI Ruixue,ZHAO Zinan,XU Wenfeng,JIN Pengfei |
| 关键字: | 子宫内膜癌;聚腺苷二磷酸核糖聚合酶抑制剂;晚期;复发性;疗效;安全性 |
| KEYWORDS: | endometrial cancer;poly(ADP-ribose) polymerase inhibitor;Advanced;Recurrent;Efficacy;Safety |
| 阅读数: | 2 次 |
| 本月下载数: | 0 次 |
* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!
返回
加入收藏










